ArticleCell biochemistry and biophysics2026
In-vitro and In-silico Evaluation of Supercritical Extract of Acacia Auriculiformis against Breast Cancer.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated computational and in vitro investigation to explore the preliminary anti-proliferative and anti-mitotic potential of γ-oryzanol against breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the preliminary effect of the supercritical fluid extract of Acacia auriculiformis (SEAA) against breast cancer. Bark samples of A. auriculiformis were subjected to supercritical-fluid extraction, and the resulting SEAA was analyzed using gas chromatography-mass spectroscopy (GC-MS). Molecular docking was conducted to assess the interaction profile of betulin and doxorubicin with P21-activated kinase 4 (PAK-4), β-cell lymphoma 2 (BCL-2), and Schlafen-12 (SLFN-12). The cytotoxic and anti-proliferative effects of SEAA were examined through the brine shrimp lethality assay and Allium cepa assay. Three doses of SEAA (100 µg/mL, 200 µg/mL, and 300 µg/mL), methotrexate (100 µg/mL) as a standard group, and 0.7% saline as a normal control (NC) group were selected for both assays. The effect of SEAA on cell viability in tumor cells was evaluated through MTT assay on MCF-7 and HT-29 cell lines. GC-MS analysis confirmed the presence of betulin at a retention time of 5.662 min. Betulin and doxorubicin demonstrated similar interaction profiles with PAK-4, BCL-2 and SLFN-12. SEAA treatment significantly (P-value < 0.05) reduced nauplii survival and increased relative lethality. SEAA (100 µg/mL) and SEAA (200 µg/mL) treatments significantly (P-value < 0.05) reduced the number and length of roots, while SEAA (300 µg/mL) treatment produced the maximum reduction in the number (P-value < 0.01) and length (P-value < 0.05) of roots comparable with methotrexate (100 µg/mL) treatment. SEAA demonstrated a dose-dependent reduction of cell viability in MCF-7 and HT-29 cell lines. SEAA treatment demonstrated preliminary cancer-protective potential through in-silico and in-vitro assays.
Indexed as
Identifiers
40952444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.